The San Diego–based continuous glucose monitoring (CGM) technology company reported a loss of $10.5 million, or $0.12 per share, on sales of $336.4 million for the three months ended June 30. Sales were up 39% compared with Q2 2018, which saw profits of $30.2 million, or $0.34 per share.
Adjusted to exclude one-time items, earnings per share were $0.08, 8¢ ahead of The Street, where analysts were looking for sales of $304.4 million.
“Dexcom generated another outstanding quarter of growth as physicians and people with diabetes continue to embrace real-time CGM and the demonstrated benefits of Dexcom’s G6 system,” Dexcom CEO Kevin Sayer said in a news release.
Dexcom expects to log a non-GAAP operating margin of roughly 7% this year, versus previous expectations of 6%, and upped its top-line outlook to $1.325 billion to $1.375 billion, compared with $1.25 billion to $1.30 billion previously.